Sanofi (NASDAQ:SNY) Shares Acquired by Zions Bancorporation N.A.

Zions Bancorporation N.A. lifted its position in Sanofi (NASDAQ:SNY) by 7.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 165,350 shares of the company’s stock after acquiring an additional 10,990 shares during the period. Zions Bancorporation N.A.’s holdings in Sanofi were worth $7,975,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Abel Hall LLC raised its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares during the last quarter. Keudell Morrison Wealth Management increased its holdings in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the last quarter. Bailard Inc. lifted its position in Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after buying an additional 220 shares in the last quarter. Old Port Advisors boosted its stake in Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after buying an additional 232 shares during the last quarter. Finally, ORG Partners LLC grew its holdings in Sanofi by 17.7% in the 4th quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock valued at $81,000 after buying an additional 253 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Down 1.7 %

Shares of NASDAQ:SNY opened at $55.93 on Tuesday. The business has a 50-day moving average price of $54.70 and a 200 day moving average price of $52.84. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $141.94 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SNY. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday. They set a “neutral” rating and a $65.00 price target on the stock. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.